A Phase 3, Open-Label, Multicenter, Extension Study of Acoramidis in Patients With Newly Diagnosed Variant Transthyretin Amyloid Cardiomyopathy (ACT-EARLY OLE)

The AG10-504 study is an open-label extension study of acoramidis in participants with newly diagnosed transthyretin amyloid cardiomyopathy (ATTR-CM) or both ATTR-CM and transthyretin amyloid polyneuropathy (ATTR-PN).

Start Date01 Nov 2025

Sponsor / Collaborator

Eidos Therapeutics, Inc.

NCT06563895

/ RecruitingPhase 3

A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial)

Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque- like substance that accumulates in different organs in the body and can cause damage to the organ. There are two ways that the TTR protein can fall apart. One way occurs as a person ages, where the normal TTR protein can fall apart and form amyloid that may no longer be sufficiently cleared by the body. This type of ATTR is known as wild-type ATTR (ATTRwt). The other way occurs when a person inherits a defective TTR gene that causes the TTR protein to spontaneously fall apart. This form of the disease is known as variant ATTR (ATTRv) and can be detected in adults by a genetic test of their TTR gene before they age.
Amyloid build-up in the heart causes the heart wall to become thick and stiff and can result in heart failure and even death. Accumulation of TTR amyloid in the heart is known as transthyretin amyloid cardiomyopathy or ATTR-CM. Amyloid can also deposit in the nerve tissues leading to nerve problems. Accumulation of TTR in the nerves is known as transthyretin amyloid polyneuropathy or ATTR-PN.
Acoramidis is an experimental drug designed to bind tightly to TTR in the blood and stabilize its structure, so it does not form the harmful amyloid plaques that can cause damage to organs.
This study is intended to determine if treatment with acoramidis in participants with ATTRv who have not yet developed any symptoms of disease can prevent or delay the development of ATTR-CM or ATTR-PN disease. If adults with an inherited defective TTR gene are treated early before any of the symptoms of disease have developed, it may be possible to delay the onset or prevent the disease entirely.

Start Date12 May 2025

Sponsor / Collaborator

Eidos Therapeutics, Inc.

ISRCTN11628974

/ CompletedPhase 1

A multiple dose study to evaluate the pharmacokinetics of an acoramidis (AG10) modified release tablet formulation in healthy subjects

Start Date30 Aug 2022

Sponsor / Collaborator

Eidos Therapeutics, Inc.

100 Clinical Results associated with Acoramidis

100 Translational Medicine associated with Acoramidis

100 Patents (Medical) associated with Acoramidis

Literatures (Medical) associated with Acoramidis

01 Dec 2025·Current heart failure reports

Etiological Treatment of Cardiac Amyloidosis: Standard of Care and Future Directions

Review

Author: Morfino, Paolo ; Emdin, Michele ; Vergaro, Giuseppe ; Chubuchna, Olena ; Aimo, Alberto ; Castiglione, Vincenzo ; Buda, Gabriele ; Ferrari Chen, Yu Fu ; Fabiani, Iacopo

Abstract:

Purpose of Review:

Cardiac amyloidosis (CA) is a condition caused by interstitial infiltration of misfolded proteins structured into amyloid fibrils. Transthyretin (ATTR) and immunoglobulin light chain (AL) amyloidosis represent the most common forms of CA. CA was traditionally perceived as a rare and incurable disease, but diagnostic and therapeutic advances have undermined the conventional paradigm.

Recent Findings:

The standard of care for ATTR-CA include agents capable of selectively stabilizing the precursor protein (e.g., tafamidis), whereas the plasma cell clone is the main target of chemotherapy for AL-CA. For long, tafamidis represented the only drug approved for patients with ATTR-CA. Recent data from ATTRibute-CM led to the approval of acoramidis, whereas patisiran received refusal based on the APOLLO-B trial. Novel CRISPR-Cas9-based drugs (i.e., NTLA-2001) hold great potential in the setting of ATTR-CA. Several hematological regimens are available to treat AL-CA. The main limit of current therapies is their inability to trigger removal of amyloid from tissues. However, the investigation of monoclonal antibodies targeting misfolded ATTR (e.g., PRX004, NI301A) or AL (e.g., birtamimab, anselamimab) has led to encouraging results.

Summary:

Various cutting-edge strategies are being tested for treatment of CA and may change the prognostic landscape of this condition in the next years.

01 Dec 2025·MOLECULAR BIOLOGY REPORTS

Transthyretin as a therapeutic target: the future of disease-modifying therapies for Alzheimer’s disease

Review

Author: Shaw, Swetaleena ; Aran, Khadga Raj ; Porel, Pratyush

BACKGROUND:

Alzheimer's disease (AD) is the most common neurodegenerative disease for causing memory deficits and primarily characterized by extracellular deposition of amyloid-β (Aβ) plaques, intracellular neurofibrillary tangles (NFTs), and hyperphosphorylation of tau protein, all are pathological hallmarks for AD. Transthyretin (TTR) is a highly conserved homo-tetrameric protein, primarily synthesized in liver and choroid plexus, and most importantly involved in transport of T₃-T₄ hormones and retinol.

OBJECTIVES:

This review explores the dual role of TTR, with a greater emphasis on its neuroprotective action, particularly in AD.

METHODS:

Based on the available literature, TTR's potential as a biomarker in the central nervous system (CNS), focusing its role in stabilizing Aβ aggregation and the senile plaque formation during neurodegeneration. Additionally, TTR's dual roles, in neurodegeneration and neuroprotection are studied, emphasizing its potential for improving AD diagnosis and treatment strategies.

RESULTS:

Recent research has revealed that TTR is gradually showcasing its promise in neuroprotection and neuronal viability in AD by binding with Aβ and mitigating its neurotoxic effects. Current preclinical and clinical studies also support that TTR is actively involved in maintaining the blood-brain barrier (BBB) integrity and maintain neurotransmitter balance, all of which offer significant therapeutic promise through TTR stabilizers, such as Tafamidis, Acoramidis, and Vutrisiran, highlighting their potential in AD treatment CONCLUSION: This review concludes that TTR plays bidirectional role and gaining interest as a potential biomarker, though several challenges must be addressed before it can be established a novel therapeutic target in AD management in the modern era of drug discovery.

01 Jun 2025·DRUGS

Acoramidis: First Approval

Review

Author: Lee, Arnold

Disassociation of transthyretin (TTR) has been identified as a key step in the pathology of TTR amyloid cardiomyopathy, which is characterised by the presence of amyloid fibrils in cardiac tissue. Acoramidis (ATTRUBY™) is a small molecule TTR stabiliser being developed by BridgeBio Pharma, Inc. and is the first drug to demonstrate near-complete (> 90%) stabilisation of TTR. This article summarizes the milestones in the development of acoramidis leading to its first approval in the USA for the treatment of the cardiomyopathy of wild-type or variant TTR-mediated amyloidosis in adults to reduce cardiovascular death and cardiovascular-related hospitalization. In the EU, a positive opinion has been adopted for the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy.

180

News (Medical) associated with Acoramidis

31 Oct 2025

·endpoints.news

The BridgeBio and Alnylam rivalry in ATTR-CM may not be a race at all. What gives?

The much-ballyhooed competition between BridgeBio and Alnylam has been less of a tug-of-war and more of a rising-tide-lifts-all-boats scenario. That’s because both companies are hitting the milestones they each laid out for the respective launches of their transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) treatments, and that’s likely to continue, even as other companies attempt to enter the market, analysts tell Endpoints News . For BridgeBio, the commercial success of Attruby — combined with two late-stage rare disease wins this week — underscore the company’s increasingly diverse portfolio. Alnylam, meanwhile, is headed toward its long-stated goal of becoming profitable by the end of this year. “We’re definitely, I’d say, poised to achieve this goal that we set out for ourselves back in 2021,” Alnylam CEO Yvonne Greenstreet told Endpoints News . Attruby and Alnylam’s Amvuttra, which both received approval for ATTR-CM within the last year, continue to record strong sales and quarter-over-quarter growth. Amvuttra generated $685 million in sales in the third quarter, up from $492 million in the second quarter, and Attruby pulled in $108.1 million compared to $71.5 million in Q2. But the raw sales numbers don’t tell the whole story. Amvuttra costs more than twice as much as Attruby. Amvuttra is also covered by Medicare Part B, while Attruby is covered by Part D. Part B drugs are typically more expensive because they’re administered in doctors’ offices, and clinicians have a different set of incentives to prescribe them. Attruby is also a small molecule drug, which is typically cheaper to manufacture than other drugs. (Amvuttra is an RNA silencer.) What’s really driving the growth for both drugs is a significant increase in the number of patients being diagnosed, according to TD Cowen analyst Ritu Baral. Some investors theorized that ATTR-CM was underdiagnosed. Even after the first ATTR-CM drug was approved in 2019 — Pfizer’s Vyndamax/Vyndaqel franchise — it was primarily prescribed to patients with severe symptoms. That created an opening for both drugs to record strong early sales despite near-simultaneous launches, Baral said. But investor skepticism also drove the idea there would be stiff competition, she added. The market potential “just wasn’t recognized by the investors, where it was by the doctors,” Baral said. Most analysts say the key metric to watch is related to underdiagnoses. The goal is to grow the number of “first-line” individuals on a drug rather than simply count the patients who switch from Vyndamax/Vyndaqel. That’s happening, according to William Blair analyst Myles Minter, because there are so many undiagnosed patients. “The moment that I start hearing all these companies going, ‘Hey, the majority of our patients are switches,’ then I’ll start to get worried,” he said. “Because then you’re just fighting for a smaller piece of the pie.” In a third-quarter earnings call, BridgeBio CEO Neil Kumar said his “best guess” of Attruby’s first-line market share is “well in the 20s” in terms of percentage of market share. Kumar said he couldn’t give a precise figure, because Alnylam and Pfizer hadn’t yet reported their earnings. (Pfizer is set to report on Tuesday.) Alnylam did not break down the first-line and “switch” figures in Thursday’s earnings call, but Greenstreet told Endpoints that Amvuttra is “highly competitive” in that “first-line” segment. Despite the strong sales figures for each drug, BridgeBio and Alnylam’s stock prices both dropped on Thursday after Alnylam reported its quarterly results. BridgeBio $BBIO shares closed down 4.9%, while Alnylam $ALNY fell about 6.7%. It’s unclear why this happened. More than a handful of analysts, including Cantor Fitzgerald’s Olivia Brayer, put out notes to investors saying investor expectations have become inflated, particularly for Alnylam. Some are “starting to question” how much upside is left in Alnylam’s stock, given the company likely won’t launch another drug for several years, Brayer wrote. Leerink analyst Mani Foroohar agreed, saying investors seemed to want accelerating sales growth rather than the stable, linear growth Alnylam has shown so far. “As investor expectations got really, really high, driven by technical as well as fundamental reasons, it became tougher and tougher to hit that bar,” he told Endpoints. BridgeBio is more insulated from this dynamic, he added, because the company is closer to launching other drugs. The rare disease wins this week point to at least two new drugs coming to market sometime in 2027. Baral noted that the stock drops may have been influenced by other incentives. Attruby and Amvuttra sales are intensely scrutinized every quarter when doing so may not be warranted, given the “explosive” market that’s unfolded in the last 12 months. “Everybody’s pushing their narrative, and Alnylam has frequently been a stock that has been controversial,” Baral said. “Let’s put it that way.”

Drug ApprovalBiosimilar

29 Oct 2025

·www.fiercebiotech.com

BridgeBio hits phase 3 win for calcium deficiency candidate, plots FDA review next year

Positive data from its encaleret come two days after BridgeBio announced that its limb-girdle muscular dystrophy candidate BBP-418 had also hit all of its primary and secondary endpoints in an interim phase 3 analysis.\n BridgeBio Pharma is having a banner week, with the Bay Area company’s encaleret acing a phase 3 trial just days after another late-stage rare disease win as its eyes an FDA review in 2026. In the global phase 3 Calibrate trial, 34 out of 45 patients with autosomal dominant hypocalcemia type 1 (ADH1), a rare genetic disease that causes calcium deficiency, who were given encaleret achieved healthy blood and urine calcium levels, BridgeBio reported in an Oct. 29 release.That result trounced the two out of 45 of those same patients who hit the calcium targets on standard-of-care treatment. Encaleret, an oral small molecule, hit all of its primary and key secondary endpoints, BridgeBio added, was well tolerated and caused no discontinuations in the trial.The result comes two days after BridgeBio announced that its limb-girdle muscular dystrophy candidate BBP-418 had also hit all of its primary and secondary endpoints in an interim phase 3 analysis.The pharma plans to file FDA approval applications for both encaleret and BBP-418 in the first half of 2026, along with launching registrational studies of encaleret in chronic hypoparathyroidism and pediatric ADH1 next year. Submission of encaleret to the European Medicines Agency will follow the FDA filing, according to the release.In a note to clients early Wednesday, analysts with Evercore ISI said they’ve “long emphasized [BridgeBio’s] unique setup,” but this week’s series of positive readouts still came as a surprise to them. The analysts described the encaleret phase 3 result as a “clear win” that further solidifies the company’s “path to becoming a multi-product company.” The 76% responder rate seen in the study was higher than the drug’s phase 2 result of 69%, according to the analysts, who also flagged “rapid” responses and a lack of side effects leading to discontinuations. The team at Evercore ISI is now modeling $1 billion in peak sales for the drug in the indication. In ADH1, a genetic mutation causes disrupted calcium sensing, which makes calcium and parathyroid hormone levels in the blood too low while calcium levels in the urine are too high.Low blood calcium levels can lead to muscle spasms and cramping, according to MedlinePlus, while too much of the mineral in urine can cause kidney stones and kidney damage.“Unlike conventional therapy with calcium supplements and active vitamin D, encaleret not only increased and maintained both blood calcium and endogenous parathyroid hormone but also decreased and maintained urine calcium in the normal range,” Michael Mannstadt, M.D., chief of the endocrine unit at Massachusetts General Hospital, said in the release. “The consistent and clinically meaningful improvements in calcium and mineral homeostasis indicate its potential to become an important new standard of care for this patient community.”Encaleret previously scored a phase 2 win at a precarious time for BridgeBio; the pharma’s star cardiovascular asset, acoramidis, flopped a phase 3 trial at the end of 2021, leading to rounds of layoffs and a tumbling share price. Acoramidis bounced back in later analyses, ultimately snagging FDA approval for rare heart disease transthyretin amyloid cardiomyopathy in November 2024.BridgeBio will also be busy next year launching a registrational trial for encaleret in chronic hypoparathyroidism, after the candidate restored healthy calcium levels in patients with post-surgical hypoparathyroidism in a small phase 2 study led by the National Institutes of Health\'s National Institute of Dental and Craniofacial Research.In addition to the looming FDA submissions of encaleret and BBP-418, BridgeBio’s dwarfism candidate infigratinib is set to wrap up its own phase 3 trial in achondroplasia by the end of the year. Since pivoting from cancer to dwarfism, infigratinib has topped BioMarin’s approved therapy Voxzogo in a phase 2 achondroplasia trial.

Clinical ResultPhase 3Phase 2AHA

29 Oct 2025

·www.biospace.com

BridgeBio Shares Pop Again As Phase III Thyroid Drug Exceeds Investor Expectations

iStock, Alona Horkova Already sky high after the success of its limb-girdle muscular dystrophy therapy, reported on Monday, BridgeBio’s shares rose nearly 8% more as encaleret balanced calcium levels in patients with a genetic thyroid disorder. Two days after BridgeBio reported the success of a limb-girdle muscular dystrophy therapy, the genetic disease biotech is back with Phase III results showing that the small molecule therapy encaleret corrected calcium levels in patients with another rare disease called autosomal dominant hypocalcemia type 1. The main goal of the study was to reach serum and urine calcium levels within a target range. BridgeBio reported on Wednesday that 76% of patients who received encaleret reached the target at week 24 compared to 4% who received standard of care. Analaysts at Mizuho said the results have exceeded investor and the company’s expectations, writing in a note to investors on Wednesday morning that “Encaleret comfortably achieved the upside case scenario.” The results also bested previous Phase II results that showed a 69% achievement of target serum and calcium levels—a major achievement as Phase III results are typically worse than Phase II, Mizuho noted. Already sky high after the success of BBP-418 in limb-girdle muscular dystrophy (LGMD) reported on Monday, BridgeBio’s shares rose nearly 8% more to just under $70 apiece in pre-market trading Wednesday. The company’s stock has risen 18% in five days. Autosomal dominant hypocalcemia type 1 (ADH1) is an inherited type of hypoparathyroidism caused by a variant in the calcium-sensing receptor (CASR) gene, leading to an imbalance in calcium in the bloodstream and urine. The condition can cause muscle cramping and spasms, seizures and kidney failure. Patients are typically treated with calcium supplements and active vitamin D. The Phase III CALIBRATE study of 70 adult patients tested whether encaleret could increase calcium in the blood and maintain levels of endogenous parathyroid hormone (PTH), which is decreased in hypoparathyroidism. The drug did both, while also decreasing levels of calcium in the urine. On a key secondary endpoint, 91% of patients taking encaleret achieved intact PTH at week 24. Mizuho also noted that encaleret acted quickly, with 71% of participants achieving target values by day three after receiving the drug. That number reached 98% by week 20. BridgeBio said that encaleret was well tolerated with no discontinuations; 97% of participants opted to continue on into a long-term extension of the study. Mizuho said the majority of treatment-emergent adverse events were mild to moderate, with most of the serious cases appearing in the standard of care arm. Analysts at Jefferies, writing in their own note Tuesday, said there were “no surprises” from the safety data. The company plans to take the therapy to the FDA for an approval application in the first half of 2026. Jefferies believes this filing plan could suggest an approval in early 2027 and, given that BridgeBio has already held multiple meetings with the FDA, an indication covering patients 16 years and older is likely. While that application proceeds, BridgeBio will continue studying the medicine in chronic hypoparathyroidism and pediatric ADH1. Mizuho expects encaleret to bring in about $750 million in peak sales in ADH1, while Jefferies puts the figure higher at $1 billion or more. BridgeBio has said that the population of symptomatic patients is about 9,000 in the U.S., with about 3,000 of those diagnosed. A Good Week For BridgeBio The results are BridgeBio’s second Phase II win of the week. On Monday, the California biotech announced that the oral small molecule BBP-418 doubled a key biomarker in LGMD that indicates muscle stabilization. A secondary endpoint showed that the drug reduced another biomarker that indicates muscle damage. Just like with encaleret, analysts heralded the results as better than expected. Elsewhere, BridgeBio is marketing Attruby, which was approved in November 2024 to treat transthyretin amyloid cardiomyopathy (ATTR-CM). The therapy landed in a crowded market that includes Pfizer’s Vyndaqel and Alnylam’s Amvuttra. But the biotech’s oral offering has held its own, notching $71.5 million in sales in the second quarter thanks to 3,751 unique patient prescriptions in the U.S. Analysts are expecting to see growth when BridgeBio reports third quarter numbers on Wednesday afternoon. Jefferies predicts sales of $102 million. Jefferies also suggests that Attruby could become “a first-line $4 billion+ pill.” BridgeBio believes the therapy is tapping into a $20 billion market opportunity, according to slides from the company’s second quarter earnings presentation.

Clinical ResultPhase 3Drug ApprovalPhase 2

100 Deals associated with Acoramidis

External Link

KEGG	Wiki	ATC	Drug Bank
D11972	-	-	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Amyloidosis, Hereditary, Transthyretin-Related	European Union	Bayer AG	10 Feb 2025
Amyloidosis, Hereditary, Transthyretin-Related	Iceland	Bayer AG	10 Feb 2025
Amyloidosis, Hereditary, Transthyretin-Related	Liechtenstein	Bayer AG	10 Feb 2025
Amyloidosis, Hereditary, Transthyretin-Related	Norway	Bayer AG	10 Feb 2025
Transthyretin Amyloid Cardiomyopathy	United States	BridgeBio Pharma, Inc.	22 Nov 2024

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Polyneuropathies	Phase 3	United States	Eidos Therapeutics, Inc.	12 May 2025
Polyneuropathies	Phase 3	Canada	Eidos Therapeutics, Inc.	12 May 2025
Polyneuropathies	Phase 3	Denmark	Eidos Therapeutics, Inc.	12 May 2025
Polyneuropathies	Phase 3	France	Eidos Therapeutics, Inc.	12 May 2025
Polyneuropathies	Phase 3	Germany	Eidos Therapeutics, Inc.	12 May 2025
Polyneuropathies	Phase 3	Ireland	Eidos Therapeutics, Inc.	12 May 2025
Polyneuropathies	Phase 3	Italy	Eidos Therapeutics, Inc.	12 May 2025
Polyneuropathies	Phase 3	Malaysia	Eidos Therapeutics, Inc.	12 May 2025
Polyneuropathies	Phase 3	Netherlands	Eidos Therapeutics, Inc.	12 May 2025
Polyneuropathies	Phase 3	Portugal	Eidos Therapeutics, Inc.	12 May 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03860935 (ATTRibute-CM OLE, GlobeNewswire) Manual	Phase 3	Transthyretin Amyloid Cardiomyopathy	286	acoramidis	becujppvgt(qwfnomyadj): Difference (%) = -44 View more	Positive	30 Aug 2025
				Placebo
NCT03860935 (ATTRibute-CM, Pubmed \| Am J Cardiovasc Drugs)	Phase 3	Transthyretin Amyloid Cardiomyopathy	632	Acoramidis hydrochloride	qbtmpwusik(dlckatjhpj) = ubxaubrwct wfbunmgjpe (wwtilzdkgc ) View more	Positive	01 Aug 2025
NCT03860935 (ATTRibute-CM, Pubmed \| J Am Coll Cardiol)	Phase 3	Transthyretin Amyloid Cardiomyopathy sTTR levels	557	Acoramidis	wylttdnrfe(qzvhchozkj) = was associated with reduced ACM in univariate analysis (HR: 0.96 per 1 mg/dL increase in early ΔTTR; 95% CI: 0.93-0.98; P = 0.002). In the multivariate analysis, after adjusting for TTR variant status, baseline New York Heart Association functional class, baseline National Amyloidosis Centre stage, and baseline sTTR level, early ΔTTR remained independently associated with reduced ACM (P < 0.001). ytsaznufcz (udzwmznjok ) View more	Positive	01 May 2025
NCT03860935 (ATTRibute-CM, Pubmed \| J Am Coll Cardiol)	Phase 3	Transthyretin Amyloid Cardiomyopathy \| Senile cardiac amyloidosis N-terminal pro-B-type natriuretic peptide level	632	Acoramidis hydrochloride 800 mg twice daily	cezzgxgxhj(fkydnwoavi): relative risk ratio = 50 (95% CI, 0.36 - 0.7), P-Value = < 0.0001 View more	Positive	01 Mar 2025
				Placebo
NCT04622046 (CTgov)	Phase 3	Transthyretin Amyloid Cardiomyopathy	25	ALXN2060	nqtmmkjpsa(pbithzrgwz) = workscqqvn tmjcddibon (ipmrkwfrsg, 9.182) View more	-	16 Dec 2024
NCT03860935 (FDA_CDER) Manual	Phase 3	Transthyretin Amyloid Cardiomyopathy	611	ATTRUBY 712 mgATTRUBY 712 mg	gxomovbcee(krlyuvugbc): P-Value = 0.018 View more	Positive	22 Nov 2024
				Placebo
NCT03860935 (ATTRibute-CM, Company_Website) Manual	Phase 3	Transthyretin Amyloid Cardiomyopathy	389	Acoramidis	ljnggygwsz(cdraftgxae) = vgkgdnneer rvupjfyvez (reqpqnsjcv ) View more	Positive	18 Nov 2024
				Placebo	-
NCT03860935 (ATTRibute-CM, GlobeNewswire \| PipelineReview) Manual	Phase 3	Transthyretin Amyloid Cardiomyopathy	-	Acoramidis	befdfjwoll(oxydodpxnv) = wvxonxfxqb xfmyyubvlm (nyznivufwy )	Positive	27 Sep 2024
				Placebo	-
NCT03860935 (ATTRibute-CM, ESC2024)	Phase 3	Transthyretin Amyloid Cardiomyopathy serum TTR levels	611	Acoramidis	karfnyrfya(bngunhbphm) = yygvwxxtqh rvryhogipc (mnmsdzcvmn )	Positive	30 Aug 2024
				Tafamidis	karfnyrfya(bngunhbphm) = hmylqdhquz rvryhogipc (mnmsdzcvmn, 0.4 (4.92))
NCT03860935 (ATTRibute-CM OLE \| ATTRibute-CM, CTgov)	Phase 3	Transthyretin Amyloid Cardiomyopathy \| Senile cardiac amyloidosis	632	acoramidis (Acoramidis HCl 800 mg)	jkhajhyjll = vqqhzesozk iqshylawvp (ukhdtqgnig, megkpwasew - qveuefmqrb) View more	-	27 Jun 2024
				Placebo Oral Tablet (Placebo)	jkhajhyjll = dztsqzgdjf iqshylawvp (ukhdtqgnig, kqhwchzkaw - yxkoonpije) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis